2025 ICD-10-CM code D61.810
(Active) Effective Date: N/A Revision Date: N/A Deletion Date: N/A Hematologic Disorders - Aplastic and other anemias and other bone marrow failure syndromes III Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism Feed
Antineoplastic chemotherapy-induced pancytopenia is a blood disorder causing decreased red blood cells, white blood cells, and platelets due to bone marrow suppression from chemotherapy.
Modifiers may be applicable depending on the circumstances of the treatment and services provided.Consult the official guidelines for appropriate modifier usage.
Medical necessity is established by the presence of pancytopenia secondary to antineoplastic chemotherapy. The severity of the cytopenias and associated clinical manifestations (fatigue, infections, bleeding) determine the intensity of interventions.
The clinical responsibility includes diagnosis through history, physical examination, and laboratory tests (CBC, peripheral blood smear, bone marrow biopsy if indicated). Treatment involves managing symptoms, providing supportive care (e.g., blood transfusions), administering medications to stimulate blood cell production, and potentially bone marrow transplantation in severe cases.Regular monitoring of blood counts and overall health is crucial.
- III Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- D60-D64 Aplastic and other anemias and other bone marrow failure syndromes
In simple words: Chemotherapy sometimes causes a blood disorder called antineoplastic chemotherapy-induced pancytopenia. This means your body makes fewer red blood cells (carrying oxygen), white blood cells (fighting infection), and platelets (helping blood clot).Symptoms can include tiredness, easy bruising, and infections. Treatment depends on how severe it is and may include blood transfusions or medication to boost blood cell production.
Antineoplastic chemotherapy-induced pancytopenia is a hematologic disorder characterized by a reduction in the production of red blood cells (RBCs), white blood cells (WBCs), and platelets, resulting from bone marrow suppression caused by certain antineoplastic drugs used in chemotherapy.The clinical presentation may include weakness, fatigue, dizziness, fever, shortness of breath, pallor, bruising, petechiae, purpura, epistaxis (nosebleeds), tachycardia (rapid heart rate), confusion, and seizures. Diagnosis is based on a comprehensive history, physical examination, complete blood count (CBC), peripheral blood smear, and potentially a bone marrow biopsy. Treatment strategies vary depending on the severity of bone marrow suppression and the patient's response to therapy, ranging from supportive care and blood transfusions to medications stimulating blood cell production and, in severe cases, bone marrow transplantation.
Example 1: A 60-year-old female with breast cancer receiving doxorubicin-based chemotherapy develops fatigue, pallor, and easy bruising.CBC reveals pancytopenia. Bone marrow biopsy shows hypoplasia.Treatment consists of growth factors and supportive care., A 55-year-old male with leukemia undergoing intensive chemotherapy experiences fever and severe neutropenia.He requires hospitalization for intravenous antibiotics and granulocyte colony-stimulating factor (G-CSF) to manage the infection and stimulate neutrophil production., A 45-year-old female with lymphoma receiving high-dose chemotherapy develops severe pancytopenia requiring red blood cell, platelet, and white blood cell transfusions.She also needs close monitoring for potential infections.
Complete blood count (CBC) with differential, peripheral blood smear, bone marrow biopsy (if indicated), detailed history of chemotherapy regimen, documentation of symptoms (fatigue, bruising, infections), and treatment provided (blood transfusions, growth factors, antibiotics, etc.).
** This code is used to report pancytopenia specifically caused by antineoplastic chemotherapy.It is crucial to accurately document the type and dose of chemotherapy administered to support the diagnosis.The severity of pancytopenia influences the choice of treatment.
- Payment Status: Active
- Modifier TC rule: Not applicable to this diagnosis code.
- Specialties:Hematology/Oncology
- Place of Service:Inpatient Hospital, Outpatient Hospital, Ambulatory Surgical Center, Physician's Office